&NA;SCH 56592 is an orally active triazole derivative that is in clinical trials with Schering-Plough in Canada and the US for the treatment of oral candidiasis. It is also undergoing preclinical investigation for the treatment of aspergillosis. In addition, SCH 56592 has potential in the treatment of Chagas disease, a condition caused by the protozoan parasiteTrypanosoma cruzi, and preclinical investigation is underway for this indication in Venezuela.